Previous 10 | Next 10 |
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today provid...
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease Selected for Oral and Late-breaking Presentations - SAN DIEGO, March 12...
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announc...
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...
The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with this event. For further details see: Crinetics Pharmaceuticals (CRNX) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - - Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 - - Initiation of Pha...
Gainers: [[ISR]] +67.9%. [[CRNX]] +7.9%. [[SCPE]] +6.3%. [[SCYX]] +6.1%. [[ENSV]] +5.3%.Losers: [[MXC]] -11.5%. [[CLSD]] -10.0%. [[DWSN]] -9.9%. [[IRIX]] -8.9%. [[TITN]] -6.6%. For further details see: ISR, CRNX, MXC and CLSD among after-hours movers
Gainers: [[OBLN]] +81%. [[MRIN]] +9.8%. [[FATE]] +8.8%. [[CRNX]] +6.7%. [[PROG]] +6.1%.Losers: [[HX]] -6.2%. [[INN]] -6.2%. [[RIDE]] -5.6%. [[MBIO]] -4.4%. [[EVK]] -3.8%. For further details see: RIDE, FATE, MBIO and MRIN among after-hours movers
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below: About Crinetics Pharmaceuticals ...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...